Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Coric

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
Advances in Therapy|November 23, 2022
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)Lauren C Powell, Gilbert L'Italien, Evan Popoff, et al.
Biological Psychiatry|December 13, 2006
Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administrationRasmon Kalayasiri, Atapol Sughondhabirom, Ralitza Gueorguieva, et al.
Headache|August 18, 2020
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for MigraineGary Berman, Robert Croop, David Kudrow, et al.
Complex Psychiatry|April 27, 2023
Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress ModelsYashika Bansal, Corey Fee, Keith A Misquitta, et al.
Psychopharmacology|December 24, 2005
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorderDaniel L Lafleur, Christopher Pittenger, Ben Kelmendi, et al.
Lancet (London, England)|July 18, 2019
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialRobert Croop, Peter J Goadsby, David A Stock, et al.
Biological Psychiatry|August 31, 2007
Systematic review: pharmacological and behavioral treatment for trichotillomaniaMichael H Bloch, Angeli Landeros-Weisenberger, Philip Dombrowski, et al.
The Lancet. Neurology|February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trialRichard B Lipton, Robert Croop, David A Stock, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
Cephalalgia : an International Journal of Headache|February 5, 2023
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trialsRichard B Lipton, Andrew Blumenfeld, Christopher M Jensen, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
Advances in Therapy|November 23, 2022
Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)Lauren C Powell, Gilbert L'Italien, Evan Popoff, et al.
Biological Psychiatry|December 13, 2006
Dopamine beta-hydroxylase gene (DbetaH) -1021C-->T influences self-reported paranoia during cocaine self-administrationRasmon Kalayasiri, Atapol Sughondhabirom, Ralitza Gueorguieva, et al.
Headache|August 18, 2020
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for MigraineGary Berman, Robert Croop, David Kudrow, et al.
Complex Psychiatry|April 27, 2023
Prophylactic Efficacy of Riluzole against Anxiety- and Depressive-Like Behaviors in Two Rodent Stress ModelsYashika Bansal, Corey Fee, Keith A Misquitta, et al.
Psychopharmacology|December 24, 2005
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorderDaniel L Lafleur, Christopher Pittenger, Ben Kelmendi, et al.
Lancet (London, England)|July 18, 2019
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialRobert Croop, Peter J Goadsby, David A Stock, et al.
Biological Psychiatry|August 31, 2007
Systematic review: pharmacological and behavioral treatment for trichotillomaniaMichael H Bloch, Angeli Landeros-Weisenberger, Philip Dombrowski, et al.
The Lancet. Neurology|February 21, 2023
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trialRichard B Lipton, Robert Croop, David A Stock, et al.
Neurology and Therapy|September 17, 2024
Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying TherapiesSamuel P Dickson, Craig H Mallinckrodt, Basia Rogula, et al.
Cephalalgia : an International Journal of Headache|February 5, 2023
Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trialsRichard B Lipton, Andrew Blumenfeld, Christopher M Jensen, et al.
Pageof 9